The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 4, 1999, Pages 428-438

  Barditch Crovo, Patricia ^a,b,c   Trapnell, Carol Braun ^a,b   Ette, Ene ^a,b   Zacur, Howard A ^a,b   Coresh, Joseph ^a,b   Rocco, Laura E ^a,b   Hendrix, Craig W ^a,b   Flexner, Charles ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; MESTRANOL PLUS NORETHISTERONE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; RIFABUTIN; RIFAMPICIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; FOLLITROPIN RELEASE; HUMAN; LIVER FUNCTION; LUTEINIZING HORMONE RELEASE; MYCOBACTERIOSIS; NEUTROPENIA; ORAL CONTRACEPTION; OVULATION INHIBITION; PATIENT COMPLIANCE; PRIORITY JOURNAL; STEADY STATE;

EID: 0032969747     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70138-4     Document Type: Article

References (41)

1. 1. Altschuler SL, Valenteen JW. Amenorrhea following rifampin administration during oral contraceptive use. Obstet Gynecol 1974;44:771-2.
2. 2. Drug interaction with oral contraceptive steroids [editorial]. Br Med J 1980;6233:93-4.
3. 3. Baciewicz AM, Self TH. Rifampin drug interactions. Arch Intern Med 1984;144:1667-71.
4. 4. Skolnick JL, Stoler BS, Katz DB, Anderson WH. Rifampin, oral contraceptives, and pregnancy. JAMA 1976;236:1382.
5. 5. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18: 472-84.
6. 6. Back DJ, Breckenridge AM, Orme ML. Drug interactions involving oral contraceptive steroid therapy. In: JC Petrie, editor. Nervous system, endocrine system and infusion therapy: clinically important adverse drug interactions; vol 2, chapter 14. Amsterdam: Elsevier Science; 1984. p. 305-27.
7. 7. Joshi JV, Joshi UM, Sankolli GM, Gupta K, Rao AP, Hazari K, et al. A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drugs. Contraception 1980;21:617-29.
8. 8. Back DJ, Breckenridge AM, Crawford F, MacIver M, Orme ML, Park BK, et al. The effect of rifampicin on norethisterone pharmacokinetics. Eur J Clin Pharmacol 1979;15:193-7.
9. 9. Back DJ, Breckenridge AM, Crawford FE, Hall JM, MacIver M, Orme ML, et al. The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception 1980;21:135-43.
10. 10. Bolt HM, Bolt M, Kappus H. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol 1977;85:189-97.
11. 11. Bolt HM, Kappus H, Bolt M. Effect of rifampicin treatment on the metabolism of oestradiol and 17α-ethinyloestradiol by human liver microsomes. Eur J Clin Pharmacol 1975;8:301-7.
12. 12. Guengerich FP. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33:500-8.
13. 13. Stadel BV, Sternthal PM, Schlesselman JJ, Douglas MB, Hall WD, Kaul L, et al. Variation of ethinylestradiol blood levels among healthy women using oral contraceptives. Fertil Steril 1980;33:257-60.
14. 14. Orme ML. The clinical pharmacology of oral contraceptive steroids. Br J Clin Pharmacol 1982;14:13-42.
15. 15. Orme ML, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet 1983;8:95-136.
16. 16. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992;22:47-65.
17. 17. Zacur HA, Burkman RT, Kimball AW, Kwiterovich P, Bell WR. Existence of multiple peaks in plasma ethinyl estradiol and norethindrone after oral administration of a contraceptive pill. J Clin Endocrinol Metab 1992;75: 1268-72.
18. 18. Shenfield GM. Drug interactions with oral contraceptive preparations. Med J Aust 1986;144:205-11.
19. 19. Miller DM, Helms SE, Brodell RT. A practical approach to antibiotic treatment in women taking oral contraceptives. J Am Acad Dermatol 1994;30:1008-11.
20. 20. Shenfield GM. Oral contraceptives: are drug interactions of clinical significance? Drug Saf 1993;9:21-37.
21. 21. Koudriakova T, Iatsimirskaia E, Tulebaev S, Spetie D, Utkin I, Mullet D, et al. In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. J Pharmacol Exp Ther 1996;279:1300-9.
22. 22. Benedetti MS. Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol Res 1995;32:177-87.
23. 23. Perucca E, Grimaldi R, Frigo GM, Sardi A, Mönig H, Ohnhaus EE. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988;34:595-9.
24. 24. Oesch F, Arand M, Benedetti MS, Castelli MG, Dostert P. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 1996;37:1111-9.
25. 25. Brogden RN, Fitton A. Rifabutin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:983-1009.
26. 26. Flexner C. Drug therapy: HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
27. 27. Bartlett JG. Management of opportunistic infections and miscellaneous conditions in medical management of HIV infection. Baltimore: Port City Press; 1997. p. 79-104.
28. 28. Szasz GZ. Samples, reagents, assessment of results. In: Bergmeyer HU, editor. Methods of enzymatic analysis; vol 2. 2nd ed. New York: John Wiley; 1974. p. 715-20.
29. 29. Moutos D, Smith S, Zacur H. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial. Contraception 1995;52:105-9.
30. 30. Reference ranges. Quest Service Manual [internal publication]. Baltimore: Quest Diagnostics; 1997.
31. 31. de la Rey N, Schall R, Luus HG, Meyer BH, Muller FO. Assessing the risk of ovulation in interaction studies of drugs and oral contraceptives. Int J Clin Pharmacol Ther Toxicol 1993;31:435-9.
32. 32. Berning SE, Peloquin CA. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease [abstract]. Clin Infect Dis 1996;22:885.
33. 33. Apseloff G, Foulds G, LaBoy-Goral L, Kraut E, Vincent J. Severe neutropenia caused by recommended prophylactic doses of rifabutin [abstract]. Lancet 1996;348:685.
34. 34. Griffith DE, Brown BA, Wallace RJ Jr. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus - negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. Clin Infect Dis 1996;23:1321-2.
35. 35. Tansey MJ, Moe JB. Severe neutropenia and prophylactíc doses of rifabutin. Lancet 1996;348:1592-3.
36. 36. LeBel M, Masson E, Guilbert E, Vallée F, Narang PK. Drug interaction between oral contraception (Ortho-Novum 1/35) and rifamycins: rifabutin versus rifampicin [abstract]. Clin Pharmacol Ther 1998;63:161.
37. 37. Murphy AA, Cropp CS, Smith BS, Burkman RT, Zacur HA. Effect of low-dose oral contraceptive on gondotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril 1990;53:35-9.
38. 38. Shenfield GM, Griffin J, Lyons J, Boutagy J. Plasma hormone concentrations in women on the oral contraceptive pill [abstract]. Eur J Clin Pharmacol 1989;36(suppl):A93.
39. 39. Bentley GR. Ranging hormones: do hormonal contraceptives ignore human biological variation and evolution? Ann NY Acad Sci 1994;709:201-3.
40. 40. Hansen TH, Lundvall F. Factors influencing the reliability of oral contraceptives. Acta Obstet Gynecol Scand 1997;76:61-4.
41. 41. Park BK, Breckenridge AM. Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 1981;6:1-24.